Development and clinical data from the European Healthcare company AOP Orphan form the basis of the introduction of a new drug in Canada for rapid heart rate control in the hospital setting. Trimedic Therapeutics is about to become the Canadian market authorization holder and exclusive distributor.

Vienna, February 1, 2021. Strokes, heart failure, heart attacks and sepsis are four of the six leading causes of hospital deaths according to the Canadian Institute for Health Information. AOP Orphan Pharmaceuticals AG (AOP Orphan) has been conducting several clinical studies to further confirm the important benefits of a super-selective, short-acting and rapidly reversible beta-blocker for patients in acute care. The medication is administered intravenously and fulfills an unmet medical need: “It is administered in life-critical conditions, where it is desirable to safely and rapidly reduce heart rate with minimal effect on blood pressure. Our new partner Trimedic Therapeutics can build on our expertise. We are happy to be able to support hospitalized patients in Canada through this strong partnership and to bring this innovative European medicine to Canada,” says Andreas Steiner, CEO of AOP Orphan.

Expansion to North America

“We are always looking for products that may offer a unique delivery and greater benefit to the physician, the health system, and especially the patient. It will be the first beta blocker introduced in Canada in more than 20 years. The actual agreement with AOP Orphan meets our needs in this regard,” comments Marty Tenenbaum, president and founder of Trimedic Therapeutics Inc of Toronto Canada. The deal has tremendous upside potential for the expansion of AOP Orphan to North America, it was signed in December 2020.

AOP Orphan Pharmaceuticals AG is an international pharmaceutical company with a focus on rare and special diseases. Over the past 25 years, the company has become an established provider of integrated therapy solutions from its headquarters in Vienna. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all our stakeholders on the other - especially the patients and their families but also the doctors and care professionals treating them. In the third quarter of 2020, AOP Orphan took over Amomed and SciPharm, two European health care companies, continuing its consistent path of growth into a pan-European health care group specializing in special diseases requiring a complex management.

Trimedic Therapeutics Inc is a Canadian based company with its head office in Toronto and affiliates across Canada. Trimedic Therapeutics Inc is well established to participate with the Canadian healthcare system and practitioners in the evolution of novel approaches to medicine where dated and first-line options may not currently meet all patients' needs. Trimedic is honored to have the opportunity to work with AOP Orphan Pharmaceuticals and looks forward to a long-term relationship.

Contact 
AOP Orphan Pharmaceuticals AG 
Wilhelminenstrasse 91/IIf, 1160 Vienna, Austria 

Ms. Nina Roth, MAS
Corporate Communications Manager 
nina.roth@aoporphan.com

Footnote:
Official label: Supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. Non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention.